<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387619</url>
  </required_header>
  <id_info>
    <org_study_id>JLP-1401-P1-DI</org_study_id>
    <nct_id>NCT02387619</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, multiple-dose, crossover study to investigate the pharmacokinetic
      drug interaction between rosuvastatin and telmisartan/amlodipine in healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, 2-treatment, 2-sequence, 2-period, multiple-dose, crossover design
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss , Cmax, ss of Rosuvastatin and Telmisartan, Amlodipine</measure>
    <time_frame>72hours, 144hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss of Rosuvastatin</measure>
    <time_frame>72hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of Rosuvastatin</measure>
    <time_frame>72hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Rosuvastatin</measure>
    <time_frame>72hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Rosuvastatin</measure>
    <time_frame>72hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss of Telmisartan, Amlodipine</measure>
    <time_frame>144hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of Telmisartan, Amlodipine</measure>
    <time_frame>144hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Telmisartan, Amlodipine</measure>
    <time_frame>144hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Telmisartan, Amlodipine</measure>
    <time_frame>144hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Group 1 of part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 of part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 of part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 of part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days</description>
    <arm_group_label>Group 1 of part 1</arm_group_label>
    <arm_group_label>Group 1 of part 2</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine</intervention_name>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days</description>
    <arm_group_label>Group 2 of part 1</arm_group_label>
    <arm_group_label>Group 2 of part 2</arm_group_label>
    <other_name>Twynsta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin and Telmisartan/Amlodipine</intervention_name>
    <description>Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days</description>
    <arm_group_label>Group 1 of part 1</arm_group_label>
    <arm_group_label>Group 2 of part 1</arm_group_label>
    <arm_group_label>Group 1 of part 2</arm_group_label>
    <arm_group_label>Group 2 of part 2</arm_group_label>
    <other_name>Crestor and Twynsta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~55 years healthy male

          -  Body weight is over 55kg, The result of Body Mass Index(BMI) is not less than 18 kg/m2
             , no more than 27 kg/m2

          -  Subjects who agree to keep contraceptive methods during the clinical trial.

        Exclusion Criteria:

          -  Subjects who are allergic to investigational drug.

          -  Subjects who have a medical history which can affect the clinical trial.

          -  Hypertension(Systolic BP ≥ 150mmHG or Diastolic BP ≥ 100mmHg), Hypotension(Systolic BP
             ≤ 100mmHg or Diastolic BP ≤ 65mmHg)

          -  Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a
             half times.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsoo Park, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

